Typically, it is associated with disturbances in calcium and phosphorus metabolism, hyperparathyroidism, vitamin D deficiency, and the increase in serum fibroblast growth factor 23 (FGF23) levels (Kidney Disease: Improving Global Outcomes KDIGO CKD-MBD Update Work Group, 2017). This evidence concerns the gene FGF23 and Marchiafava-Bignami disease.